|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pujol JL, Barlesi F and Daurès JP: Should
chemotherapy combinations for advanced non-small cell lung cancer
be platinum-based? A meta-analysis of phase III randomized trials.
Lung Cancer. 51:335–345. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Le Chevalier T, Scagliotti G, Natale R,
Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J,
Thatcher N, et al: Efficacy of gemcitabine plus platinum
chemotherapy compared with other platinum containing regimens in
advanced non-small-cell lung cancer: A meta-analysis of survival
outcomes. Lung Cancer. 47:69–80. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ettinger DS, Akerley W, Borghaei H, Chang
AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK,
Govindan R, et al NCCN (National Comprehensive Cancer Network), :
Non-small cell lung cancer. J Natl Compr Canc Netw. 10:1236–1271.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chevalier TL, Brisgand D, Douillard JY,
Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P and
Cigolari S: Randomized study of vinorelbine and cisplatin versus
vindesine and cisplatin versus vinorelbine alone in advanced
non-small-cell lung cancer: Results of a European multicenter trial
including 612 patients. J Clin Oncol. 12:360–367. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Non-small Cell Lung Cancer Collaborative
Group, . Chemotherapy in non-small cell lung cancer: A
meta-analysis using updated data on individual patients from 52
randomised clinical trials. BMJ. 311:899–909. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cappuzzo F, Hirsch FR, Rossi E, Bartolini
S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini
I, et al: Epidermal growth factor receptor gene and protein and
gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer
Inst. 97:643–655. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern
Cooperative Oncology Group, : Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Robinson DR, Wu YM and Lin SF: The protein
tyrosine kinase family of the human genome. Oncogene. 19:5548–5557.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Valverde P, Obin MS and Taylor A: Role of
Gas6/Axl signaling in lens epithelial cell proliferation and
survival. Exp Eye Res. 78:27–37. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goruppi S, Ruaro E and Schneider C: Gas6,
the ligand of Axl tyrosine kinase receptor, has mitogenic and
survival activities for serum starved NIH3T3 fibroblasts. Oncogene.
12:471–480. 1996.PubMed/NCBI
|
|
12
|
Cano A, Pérez-Moreno MA, Rodrigo I,
Locascio A, Blanco MJ, Del Barrio MG, Portillo F and Nieto MA: The
transcription factor Snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol.
2:76–83. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goruppi S, Ruaro E, Varnum B and Schneider
C: Requirement of phosphatidylinositol 3-kinase-dependent pathway
and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3
fibroblasts. Mol Cell Biol. 17:4442–4453. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Donnell K, Harkes IC, Dougherty L and
Wicks IP: Expression of receptor tyrosine kinase Axl and its ligand
Gas6 in rheumatoid arthritis: Evidence for a novel endothelial cell
survival pathway. Am J Pathol. 154:1171–1180. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Janssen JW, Schulz AS, Steenvoorden AC,
Schmidberger M, Strehl S, Ambros PF and Bartram CR: A novel
putative tyrosine kinase receptor with oncogenic potential.
Oncogene. 6:2113–2120. 1991.PubMed/NCBI
|
|
16
|
O'Bryan JP, Frye RA, Cogswell PC, Neubauer
A, Kitch B, Prokop C, Espinosa R, Le Beau MM, Earp HS and Liu ET:
axl, a transforming gene isolated from primary human myeloid
leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell
Biol. 11:5016–5031. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shieh YS, Lai CY, Kao YR, Shiah SG, Chu
YW, Lee HS and Wu CW: Expression of axl in lung adenocarcinoma and
correlation with tumor progression. Neoplasia. 7:1058–1064. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ye X, Li Y, Stawicki S, Couto S,
Eastham-Anderson J, Kallop D, Weimer R, Wu Y and Pei L: An anti-Axl
monoclonal antibody attenuates xenograft tumor growth and enhances
the effect of multiple anticancer therapies. Oncogene.
29:5254–5264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meyer AS, Miller MA, Gertler FB and
Lauffenburger DA: The receptor AXL diversifies EGFR signaling and
limits the response to EGFR-targeted inhibitors in triple-negative
breast cancer cells. Sci Signal. 6:ra662013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Janmaat ML, Kruyt FA, Rodriguez JA and
Giaccone G: Response to epidermal growth factor receptor inhibitors
in non-small cell lung cancer cells: Limited antiproliferative
effects and absence of apoptosis associated with persistent
activity of extracellular signal-regulated kinase or Akt kinase
pathways. Clin Cancer Res. 9:2316–2326. 2003.PubMed/NCBI
|
|
21
|
Holland SJ, Pan A, Franci C, Hu Y, Chang
B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, et al: R428, a
selective small molecule inhibitor of Axl kinase, blocks tumor
spread and prolongs survival in models of metastatic breast cancer.
Cancer Res. 70:1544–1554. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Danielsen T, Hvidsten M, Stokke T, Solberg
K and Rofstad EK: Hypoxia induces p53 accumulation in the S-phase
and accumulation of hypophosphorylated retinoblastoma protein in
all cell cycle phases of human melanoma cells. Br J Cancer.
78:1547–1558. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-tie quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu MM, Mao GX, Liu J, Li JC, Huang H, Liu
YF and Liu JH: Low expression of the FoxO4 gene may contribute to
the phenomenon of EMT in non-small cell lung cancer. Asian Pac J
Cancer Prev. 15:4013–4018. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Christiansen JJ and Rajasekaran AK:
Reassessing epithelial to mesenchymal transition as a prerequisite
for carcinoma invasion and metastasis. Cancer Res. 66:8319–8326.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vandewalle C, Van Roy F and Berx G: The
role of the ZEB family of transcription factors in development and
disease. Cell Mol Life Sci. 66:773–787. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Z, Lee JC, Lin L, Olivas V, Au V,
LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al:
Activation of the AXL kinase causes resistance to EGFR-targeted
therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cerchia L, Esposito CL, Camorani S, Rienzo
A, Stasio L, Insabato L, Affuso A and de Franciscis V: Targeting
Axl with an high-affinity inhibitory aptamer. Mol Ther.
20:2291–2303. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hata A, Katakami N, Yoshioka H, Takeshita
J, Tanaka K, Nanjo S, Fujita S, Kaji R, Imai Y, Monden K, et al:
Rebiopsy of non-small cell lung cancer patients with acquired
resistance to epidermal growth factor receptor-tyrosine kinase
inhibitor: Comparison between T790M mutation-positive and
mutation-negative populations. Cancer. 119:4325–4332. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Niederst MJ and Engelman JA: Bypass
mechanisms of resistance to receptor tyrosine kinase inhibition in
lung cancer. Sci Signal. 6:10.1126/scisignal.20046522013.
View Article : Google Scholar
|
|
31
|
Qi J, McTigue MA, Rogers A, Lifshits E,
Christensen JG, Jänne PA and Engelman JA: Multiple mutations and
bypass mechanisms can contribute to development of acquired
resistance to MET inhibitors. Cancer Res. 71:1081–1091. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takeyama Y, Sato M, Horio M, Hase T,
Yoshida K, Yokoyama T, Nakashima H, Hashimoto N, Sekido Y, Gazdar
AF, et al: Knockdown of ZEB1, a master epithelial-to-mesenchymal
transition (EMT) gene, suppresses anchorage-independent cell growth
of lung cancer cells. Cancer Lett. 296:216–224. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mani SA, Guo W, Liao M-J, Eaton EN,
Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et
al: The epithelial-mesenchymal transition generates cells with
properties of stem cells. Cells. 133:704–715. 2008. View Article : Google Scholar
|
